Novel nicotine analogues with potential anti-mycobacterial activity.

[1]  J. Sacchettini,et al.  The identification of novel Mycobacterium tuberculosis DHFR inhibitors and the investigation of their binding preferences by using molecular modelling , 2015, Scientific Reports.

[2]  M. Files,et al.  Synthesis and anti-tubercular activity of 3-substituted benzo[b]thiophene-1,1-dioxides , 2014, PeerJ.

[3]  Marvin J. Miller,et al.  Bactericidal Activity of an Imidazo[1, 2-a]pyridine Using a Mouse M. tuberculosis Infection Model , 2014, PloS one.

[4]  V. Bernardes-Génisson,et al.  Isoniazid: an update on the multiple mechanisms for a singular action. , 2013, Current medicinal chemistry.

[5]  D. Sherman,et al.  Identification of New Drug Targets and Resistance Mechanisms in Mycobacterium tuberculosis , 2013, PloS one.

[6]  P. Yogeeswari,et al.  Design, synthesis, and structure-activity correlations of novel dibenzo[b,d]furan, dibenzo[b,d]thiophene, and N-methylcarbazole clubbed 1,2,3-triazoles as potent inhibitors of Mycobacterium tuberculosis. , 2012, Journal of medicinal chemistry.

[7]  S. Loewenberg.  India reports cases of totally drug-resistant tuberculosis , 2012, The Lancet.

[8]  C. Evans,et al.  A new era for global tuberculosis control , 2011, The Lancet.

[9]  J. Maurice.  WHO framework targets tuberculosis–diabetes link , 2011, The Lancet.

[10]  L. Dover,et al.  Current status and research strategies in tuberculosis drug development. , 2011, Journal of medicinal chemistry.

[11]  A. Tyagi,et al.  Identification of Inhibitors against Mycobacterium tuberculosis Thiamin Phosphate Synthase, an Important Target for the Development of Anti-TB Drugs , 2011, PloS one.

[12]  A. Ginsberg.  Drugs in Development for Tuberculosis , 2010, Drugs.

[13]  Antoine Taly,et al.  Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system , 2009, Nature Reviews Drug Discovery.

[14]  Lynn Rasmussen,et al.  High-throughput screening for inhibitors of Mycobacterium tuberculosis H37Rv. , 2009, Tuberculosis.

[15]  Sandeep Jain,et al.  Synthesis and in-vitro antibacterial activity of some novel N-nicotinoyl-1-ethyl-6-fluoro-1,4-dihydro-7-piperazin-1-yl-4-oxoquinoline-3-carboxylates. , 2008, Acta poloniae pharmaceutica.

[16]  W. Denny,et al.  A roadmap for drug discovery and its translation to small molecule agents in clinical development for tuberculosis treatment. , 2008, Tuberculosis.

[17]  Mohamed M. Abdulla,et al.  Anti-inflammatory and analgesic activities of some newly synthesized pyridinedicarbonitrile and benzopyranopyridine derivatives , 2008, Acta pharmaceutica.

[18]  V. Choubey,et al.  Antiplasmodial Activity of [(Aryl)arylsulfanylmethyl]Pyridine , 2007, Antimicrobial Agents and Chemotherapy.

[19]  Yves L Janin,et al.  Antituberculosis drugs: ten years of research. , 2007, Bioorganic & medicinal chemistry.

[20]  J. Nowakowski,et al.  Antimicrobial activity of nicotine against a spectrum of bacterial and fungal pathogens. , 2000, Journal of medical microbiology.

[21]  I. Sinha,et al.  Differentiation of non-pathogenic (biotype 1A) Yersinia enterocolitica from pathogenic bioserotypes by sodium acetate utilisation. , 2000, Journal of medical microbiology.

[22]  L. Collins,et al.  Microplate alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium , 1997, Antimicrobial agents and chemotherapy.

[23]  N. Benowitz,et al.  Metabolism of nicotine to cotinine studied by a dual stable isotope method , 1994, Clinical pharmacology and therapeutics.

[24]  M. Shigenaga,et al.  Metabolism-dependent covalent binding of (S)-[5-3H]nicotine to liver and lung microsomal macromolecules. , 1988, Drug metabolism and disposition: the biological fate of chemicals.

[25]  James C. Sacchettini,et al.  Drugs versus bugs: in pursuit of the persistent predator Mycobacterium tuberculosis , 2008, Nature Reviews Microbiology.

[26]  D. Donnelly-roberts,et al.  Stable expression, pharmacologic properties and regulation of the human neuronal nicotinic acetylcholine alpha 4 beta 2 receptor. , 1996, The Journal of pharmacology and experimental therapeutics.